The previous IMS Statement in 2004 is still valid and serves as a basis for the current Updated Recommendations.
We are aware of the geographical variations related to different priorities of medical care, different prevalence of diseases, and country-specific attitudes of the public, the medical community and the health authorities toward menopause management, which may all impact on hormone therapy. The following recommendations, therefore, give a global and simple overview that serves as a common platform on issues related to the various aspects of hormone treatment. These Recommendations were reviewed and discussed by representatives of more than 60 National and Regional Menopause Societies from all continents. These Recommendations can be easily adapted and modified according to local needs.
GOVERNING PRINCIPLES
Hormone therapy should be part of an overall strategy including lifestyle recommendations regarding diet, exercise, smoking and alcohol for maintaining the health of postmenopausal women. HT must be individualized and tailored according to symptoms and the need for prevention, as well as personal and family history, results of relevant investigations, the womans preferences and expectations. The risks and benefits of HT differ for women around the time of menopause compared to those for older women.
HT includes a wide range of hormonal products and routes of administration, with potentially different risks and benefits. Thus, the term class effect is confusing and inappropriate.
Women experiencing a spontaneous or iatrogenic menopause before the age of 45 years and particularly before 40 are at higher risk for cardiovascular disease and ost
'"/>
Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
16-May-2007